Plain-English translation of NCT05698147 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called (also called ATG-010) combined with two standard cancer drugs— and —to treat a type of brain cancer called central nervous system lymphoma that has come back or stopped responding to earlier treatment. The first part of the study figures out the right dose of the medication, and the second part tests whether this combination really works. Doctors hope this new treatment may help patients whose lymphoma has proven difficult to control.
Brain lymphoma is a rare and serious cancer that is very difficult to treat, especially when it comes back or stops responding to the initial chemotherapy. This trial exists because doctors need better options for patients in this situation, and they believe adding this medication to the standard treatment might improve outcomes.
You likely qualify if…
You likely don't qualify if…
You would first have a screening visit (up to 21 days) where doctors check your health with blood tests and imaging to make sure you qualify. Then you would receive 6 cycles of treatment, with each cycle lasting 28 days. During each cycle, you would take the new oral medication on specific days of the week and receive the two standard chemotherapy drugs by injection. After completing the 6 cycles, if your cancer improves, you may continue taking the new medication alone for up to a year to help keep the cancer under control. You will have regular follow-up visits and tests throughout the trial.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China